HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTGâs proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG EdgeSeq chemistry and automation with next-generation sequencing (NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services. Source
No articles found.
Restance is pursuing several business lines in the growing economies of East Afric...
Restance is pursuing several business lines in ...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
As a leading provider of innovative technologies for the treatment of Atrial Fibri...
As a leading provider of innovative technologie...
Repligen Corporation is a global bioprocessing company that develops and commercia...
Repligen Corporation is a global bioprocessing ...
Alterola Biotech Inc. provides medicinal delivery systems, offering nutraceutrical...
Alterola Biotech Inc. provides medicinal delive...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietar...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, ...
Join the National Investor Network and get the latest information with your interests in mind.